mTOR, a Potential Target to Treat Autism Spectrum Disorder. - Wikidata - wikimedia - TriplyDB

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

http://www.wikidata.org/entity/Q37350523

about

Autism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories.Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturge-Weber Syndrome.Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.Early postnatal exposure to isoflurane causes cognitive deficits and disrupts development of newborn hippocampal neurons via activation of the mTOR pathway.Microglia M2A Polarization as Potential Link between Food Allergy and Autism Spectrum Disorders.mTOR-Dependent Cell Proliferation in the Brain.Mechanistic target of rapamycin (mTOR): A mediator of social development.Bidirectional manipulation of mTOR signaling disrupts socially mediated vocal learning in juvenile songbirds.Untangling the most probable role for vitamin D3 in autism.Autism spectrum disorder: prospects for treatment using gene therapy.Sensory Processing Phenotypes in Fragile X Syndrome

P2860

Q33619607-7FCC6A9E-0D8F-4476-8DBF-F029E3349C1F Q37707250-C48FE5DE-2B30-4288-8C4D-F18AF7B81599 Q38905665-6B70352D-0428-418F-AE25-F3DA03761EA1 Q40951791-7187FD57-2D21-4A57-B9D8-E8076D3D3232 Q47168640-443B32B6-B760-49DA-8945-C372E3CB216F Q47231432-0A1B89D4-E0F7-47F1-BE86-94CEC212ED58 Q47730376-6194EA50-D6C4-42E9-B021-DD60986717C2 Q47768882-7CAFAFB7-FF2C-4A6B-A965-564613D7FA29 Q50301196-B56A8371-ADAB-4085-A0BB-6F6AB56AA7E7 Q55339450-131A1824-CEE2-4DBF-84CB-90A5FEAEF4C3 Q58718525-0D3DBB40-6BB1-4563-8219-703172742434

P2860

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

http://www.wikidata.org/entity/Q37350523

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

@en

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

@nl

type

label

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

@en

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

@nl

prefLabel

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

@en

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

@nl

P1433

Q37350523-36D2C188-2085-4FA4-BCDB-58E880250FD9

P1476

Q37350523-A494E429-0FC1-47EB-9A96-E18CFA0F32D0

P2093

Q37350523-5929BE6A-C725-44BA-9612-0E70BEAB095E

P275

Q37350523-303E4531-A8A1-40D5-A7C2-7BE3A4473F19

P2860

Q37350523-023B36C2-2C43-400E-89EC-6ED3D49A9FF9

Q37350523-05AAF90B-23AD-4EE8-A71D-153C12C09F4C

Q37350523-067C4076-BAAD-4726-9087-686C3DA064C6

Q37350523-07CBDD17-6FA2-46BC-BDAE-DD27DE7CFACD

Q37350523-09C8E3B3-FB3D-4456-AEDB-98E14FBAA502

Q37350523-0BA998DE-D7F2-4578-BF32-9A3112F76F0B

Q37350523-0BC790BE-764D-4DBE-B8F1-98A9EBC01482

Q37350523-0D528916-CE1B-44E8-A62B-45EC1469EED1

Q37350523-0F6A99CD-51DF-4CAB-A7A7-85A1A7FC915D

Q37350523-12ED3410-6BA6-4100-B27C-506727ABBA9D

P304

Q37350523-C701BDAA-8D43-4CBB-BF37-7E4EAA688024

P31

Q37350523-0A1C8215-20E9-40C4-99A4-B0C61417F8C9

Q37350523-F35CE625-CD70-482F-B46E-2BC79B5CE17E

P356

Q37350523-375C6A51-3E55-4D8E-85A0-AB15FD29B604

P433

Q37350523-8B28961A-53D5-401C-83D2-81C45C25E108

P478

Q37350523-0CF6286E-29FD-43A5-830F-ECF7D350CD57

P5008

Q37350523-A8A7293C-692B-46BD-B819-714E3D9A3AE3

P577

Q37350523-F6AA6B2C-F9F7-41C5-B60B-E69616B0D7F2

P698

Q37350523-3CA7F611-9A55-4BD8-A464-FD84F41E9838

P921

Q37350523-162AEE52-32F6-4BBA-8D2C-DACAE2D8AF66

Q37350523-5EB5FD66-B453-48BD-AD85-FE8838EE2BE6

Q37350523-CCC4B16E-0FA8-41D9-9EDA-2F87CB21D915

P932

Q37350523-E51D255F-CCD4-4874-A91C-84FFD102D8FC

P356

1871527315666160413120638

P1433

CNS and Neurological Disorders

P1476

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

@en

P2093

Atsushi Sato

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice.

Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53

Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles

Correction of fragile X syndrome in mice.

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products

P304

533-543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1871527315666160413120638

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27071790

http://www.w3.org/2001/XMLSchema#string

P921

Autism spectrum

P932

5070418

http://www.w3.org/2001/XMLSchema#string